Cutler Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $203K | Sell |
6,300
-18,900
| -75% | -$3.26M | 0.07% | 281 |
|
|
2023
Q4 | $183K | Buy |
25,200
+7,300
| +41% | +$1.06M | 0.02% | 776 |
|
|
2023
Q3 | $32K | Sell |
17,900
-18,900
| -51% | -$2.77M | ﹤0.01% | 1726 |
|
|
2023
Q2 | $25K | Buy |
36,800
+35,700
| +3,245% | +$5.24M | ﹤0.01% | 1705 |
|
|
2023
Q1 | $3K | Sell |
1,100
-33,300
| -97% | -$5.09M | ﹤0.01% | 2893 |
|
|
2022
Q4 | $21K | Sell |
34,400
-21,100
| -38% | -$3.24M | ﹤0.01% | 2167 |
|
|
2022
Q3 | $127K | Sell |
55,500
-52,700
| -49% | -$7.56M | 0.01% | 1218 |
|
|
2022
Q2 | $592K | Sell |
108,200
-79,300
| -42% | -$12.1M | 0.04% | 484 |
|
|
2022
Q1 | $2.82M | Buy |
187,500
+106,800
| +132% | +$15.5M | 0.15% | 143 |
|
|
2021
Q4 | $1.18M | Buy |
80,700
+30,400
| +60% | +$3.59M | 0.05% | 404 |
|
|
2021
Q3 | $130K | Sell |
50,300
-58,700
| -54% | -$6.71M | 0.01% | 1698 |
|
|
2021
Q2 | $189K | Buy |
109,000
+73,200
| +204% | +$8.24M | 0.01% | 1382 |
|
|
2021
Q1 | $105K | Sell |
35,800
-78,000
| -69% | -$8.34M | 0.01% | 1734 |
|
|
2020
Q4 | $530K | Buy |
113,800
+104,600
| +1,137% | +$10.1M | 0.03% | 601 |
|
|
2020
Q3 | $34K | Sell |
9,200
-7,000
| -43% | -$659K | ﹤0.01% | 2047 |
|
|
2020
Q2 | $171K | Sell |
16,200
-6,200
| -28% | -$546K | 0.01% | 960 |
|
|
2020
Q1 | $21K | Sell |
22,400
-1,200
| -5% | -$102K | ﹤0.01% | 2260 |
|
|
2019
Q4 | $285K | Sell |
23,600
-13,600
| -37% | -$1.13M | 0.02% | 664 |
|
|
2019
Q3 | $153K | Sell |
37,200
-71,600
| -66% | -$4.91M | 0.01% | 832 |
|
|
2019
Q2 | $117K | Buy |
108,800
+57,500
| +112% | +$4.52M | 0.01% | 1002 |
|
|
2019
Q1 | $201K | Buy |
51,300
+19,000
| +59% | +$1.55M | 0.02% | 644 |
|
|
2018
Q4 | $494K | Buy |
32,300
+10,000
| +45% | +$879K | 0.05% | 339 |
|
|
2018
Q3 | $440K | Sell |
22,300
-11,000
| -33% | -$1.04M | 0.03% | 514 |
|
|
2018
Q2 | $518K | Sell |
33,300
-34,300
| -51% | -$3.35M | 0.04% | 426 |
|
|
2018
Q1 | $624K | Buy |
67,600
+17,800
| +36% | +$1.96M | 0.05% | 346 |
|
|
2017
Q4 | $993K | Sell |
49,800
-49,400
| -50% | -$4.66M | 0.04% | 332 |
|
|
2017
Q3 | $1.23M | Buy |
99,200
+11,100
| +13% | +$845K | 0.05% | 290 |
|
|
2017
Q2 | $368K | Sell |
88,100
-662,800
| -88% | -$44.6M | 0.01% | 868 |
|
|
2017
Q1 | $927K | Buy |
750,900
+278,100
| +59% | +$17.5M | 0.04% | 413 |
|
|
2016
Q4 | $563K | Buy |
472,800
+110,700
| +31% | +$6.76M | 0.02% | 638 |
|
|
2016
Q3 | $474K | Buy |
362,100
+57,300
| +19% | +$3.71M | 0.02% | 643 |
|
|
2016
Q2 | $838K | Buy |
304,800
+13,900
| +5% | +$847K | 0.04% | 342 |
|
|
2016
Q1 | $513K | Sell |
290,900
-39,400
| -12% | -$2.2M | 0.03% | 514 |
|
|
2015
Q4 | $734K | Buy |
+330,300
| New | +$19M | 0.04% | 446 |
|
Other funds holding ABBV
Cutler Group's ABBV Position: Q1 2024 in Review
Cutler Group reduced its AbbVie (ABBV) stake by 11% in Q1 2024, selling an estimated $32.2K and leaving 1,480 shares worth $269K. The position accounts for 0.09% of the portfolio, ranked #226.
Cutler Group first reported a position in ABBV in Q4 2015 and has held it in 33 quarters since. The position peaked at $3.96M in Q4 2021. 3,379 funds tracked by Wall St. Rank hold ABBV as of Q1 2024.
- Cutler Group held 1,480 shares of AbbVie worth $269K as of Q1 2024.
- Cutler Group sold 187 AbbVie shares in Q1 2024, an estimated $32.2K.
- AbbVie made up 0.09% of Cutler Group's portfolio in Q1 2024, its #226 holding.
- Cutler Group first reported a position in AbbVie in Q4 2015 and has held it in 33 quarters since.
- Cutler Group's AbbVie position peaked at $3.96M in Q4 2021.
- 3,379 funds tracked by Wall St. Rank held AbbVie as of Q1 2024.
Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.